Annovis Bio, Inc. announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with mild to moderate Alzheimer's disease (AD). A total of 327 patients have successfully concluded the phase II/III trial out of the initial 353 enrolled.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.61 USD | -2.94% | -0.60% | -64.65% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-64.65% | 73.84M | |
+16.73% | 123B | |
+13.04% | 107B | |
-5.80% | 24.01B | |
+2.21% | 22.59B | |
-10.09% | 18.16B | |
-40.52% | 16.84B | |
-14.00% | 16.23B | |
+1.18% | 13.43B | |
+24.18% | 11.32B |
- Stock Market
- Equities
- ANVS Stock
- News Annovis Bio, Inc.
- Annovis Bio, Inc. Announces Last Patient Last Visit in Phase II/III Study of Buntanetap in Alzheimer's Disease